Angiotensin receptor antagonists: focus on losartan

The Lancet

Volumn 346, Issue 8987, 1995, Pages 1403-1407

  Johnston, C I ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2 ETHYL 5,7 DIMETHYL 3 [4 [2 (2H TETRAZOL 5 YL)PHENYL]BENZYL]IMIDAZO[4,5 B]PYRIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IRBESARTAN; LOSARTAN POTASSIUM; PEPTIDE HORMONE ANTAGONIST; TVC 116; UNCLASSIFIED DRUG; VALSARTAN;

CARDIOVASCULAR DISEASE; CHEMICAL STRUCTURE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; COUGHING; DRUG EFFICACY; ESSENTIAL HYPERTENSION; FETOTOXICITY; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; META ANALYSIS; PRIORITY JOURNAL; SHORT SURVEY; VERTIGO;

EID: 0028822833     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(95)92411-6     Document Type: Article

References (36)

1. Angiotensin-converting enzyme inhibitors in hypertension
2. Angiotensin converting enzyme inhibition
3. Human chymase: cellular localization and regional distribution of a major angiotensin II-forming enzyme in the heart
4. Angiotensin II receptors and angiotensin II receptor antagonists
5. Pharmacokinetics and biochemical efficacy after single and multiple oral administration of losartan an orally active nonpeptide angiotensin II receptor antagonist in humans
6. Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist
7. Dose-response relationships of ACE inhibitors and angiotensin II blockers
8. Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers
9. Characterisation of the angiotensin II receptor antagonist TCV-116 in healthy volunteers
10. Angiotensin II blockade in healthy volunteers: tolerability and impact on renin angiotensin system components of single and repeated doses of a new angiotensin II receptor antagonist SR47436(BMS186295)
11. Angiotensm II receptor blockade with single doses of valsartan in healthy normotensive subjects
12. Comparison of angiotensin-converting enzyme inhibition with angiotensin II receptor antagonism in the human forearm
13. Angiotensin II antagonists DuP 753 and TCV 116
14. Effects of losartan on blood pressure, plasma renin activity, and angiotensin II in volunteers
15. Dose-ranging study of the angiotensin type I receptor losartan (DuP753/MK954), in salt-deplete normal man
16. Clinical experience with the angiotensin II receptor antagonist losartan
17. Efficacy and safety of losartan in patients with essential hypertension
18. Hypotensive effect of losartan, a nonpeptide angiotensin II receptor antagonist, in essential hypertension
19. Blood pressure effects of the angiotensin II receptor blocker, losartan
20. Hemodynamic and humoral effects of the angiotensin II antagonist losartan in essential hypertension
21. Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients
22. Efficacy and safety of concomitant losartan(L) hydrochlorothiazide(H) (HCTZ) therapy in patients with essential hypertension
23. Open clinical studies on a new angiotensin II receptor antagonist, TCV 116
24. 1 receptor antagonist irbesartan in hypertension
25. Role of the renin-angiotensin system in hypertension in the elderly
26. The effect of angiotensin II receptor blockade on insulin sensitivity and sympathetic nervous system activity in primary hypertension
27. Efficacy of an angiotensin receptor antagonist, TCV-116, on sympathetic nerve activity in patients with essential hypertension
28. Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure
29. Losartan in heart failure: hemodynamic effects and tolerability
30. Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects
31. Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system?
32. Effects of an angiotensin II receptor antagonist, TCV-116, on renal haemodynamics in essential hypertension
33. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER and angiotensin converting enzyme inhibitors for the treatment of systemic hypertension
34. Effects of modulators of the renin-angiotensin-aldosterone system on cough
35. The incidence of cough with the angiotensin II receptor antagonist (Ang II RA), losartan, is significantly less than with angiotensin converting enzyme (ACE) inhibitors (ACEI) and is similar to that of placebo
36. Evolution of blockade of the renin angiotensin system